Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha-1 antitrypsin - Omni Bio Pharmaceutical

Drug Profile

Alpha-1 antitrypsin - Omni Bio Pharmaceutical

Alternative Names: p-AAT; Plasma-derived alpha 1 antitrypsin - Omni Bio Pharmaceutical

Latest Information Update: 07 Apr 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Colorado at Denver
  • Developer Colorado State University; Omni Bio Pharmaceutical; University of Colorado at Denver; Virginia Commonwealth University
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Pancreatic elastase inhibitors; Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Anthrax; Graft-versus-host disease; HIV infections; Influenza virus infections; Myocardial infarction; Pneumonia; Tuberculosis; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 Dec 2014 Interim efficacy, adverse events and pharmacodynamics data from a phase I/II trial in Graft-versus-host disease presented at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH-2014)
  • 30 Apr 2014 Final efficacy, adverse events and pharmacodynamics data from a clinical trial in Type 1 diabetes mellitus released by Omni Bio Pharmaceutical
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top